Non-invasive Test for
Colorectal Cancer

Contact Us
Why do we need ColoTect

The Importance of Colorectal Cancer Screening

Early Detection of Colorectal Cancer Saves Lives

Colorectal cancer (CRC) is the third most common cancer and the second deadliest cancer globally, with an estimated 1.9 million new cases and 935,000 new deaths in the world in 2020.1

When CRC is caught early, the 5-year relative survival rate of CRC patients can be as high as 90%.2,3,4 Major guidelines generally recommend early screening to men and women above the age of 50 who are at average risk for CRC.5,6,7

COLOTECTTM Testing Journey

COLOTECTTM is a combined human gene methylation and fecal occult blood non-invasive in vitro diagnostic (IVD) assay for qualitative detection of certain genes’ methylation and fecal hemoglobin from human stool specimens.
  • How does ColoTect work
    1.Customer/Physician orders test
  • How does ColoTect work
    2.BGI/Partner sends collection kit to customer’s address
  • How does ColoTect work
    3.Customer collects stool samples at home
  • How does ColoTect work
    4.Customer ships stool samples back to the processing laboratory
  • How does ColoTect work
    5.Laboratory conducts testing and generates report


  • 1.The data presented here comes from the Global Cancer Observatory, owned by the World Health Organization/International Agency for Research on Cancer (last accessed 17 August 2022).
  • 2.Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol. 2012;4(4):71-75. doi:10.4251/wjgo.v4.i4.71
  • 3.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708
  • 4.Survival rates for colorectal cancer. American Cancer Society. Accessed August 22, 2022.
  • 5.Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238.ssaa
  • 6.Adult Screening Programme, Bowel Cancer. UK NSC screening recommendation. Accessed August 22, 2022.
  • 7.Evidenced-based Guideline for Colorectal Cancer. Version 2.1 – January 2019 AWMF-Registration Number: 021/007OL. German Guideline Program in Oncology (GGPO). Accessed August 22, 2022.

Intended Use and Important Risk Information:

The Combined Detection Kit for Human Gene Methylation and Fecal Occult Blood is a non-invasive in vitro diagnostic (IVD) assay for qualitative detection of certain genes’ methylation and fecal hemoglobin from human stool specimens. The kit is intended to be used for screening colorectal cancer in the general population. A positive test result indicates that the subject may have colorectal cancer and/or advanced adenoma, and further colonoscopy is required; on the contrary, a negative test result indicates that the subject has a low possibility of colorectal cancer and/or advanced adenoma, however, the risk of disease cannot be completely ruled out. The product is applicable to all people between the ages of 40 to 75 who need colorectal cancer screening.

This product cannot replace colonoscopy, and the test results of this kit should not be used as the only basis for clinical diagnosis. Clinicians should comprehensively judge the results based on the patient's condition and other laboratory indicators. CE marked.